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Studies on the pathogenesis of emerging viruses that present a global threat are critical for
pathogen classification and therapeutic development. Humanized mice enable investigation of
viral pathogens, including Human immunodeficiency virus (HIV-1), Zika virus (ZIKV), Coronavirus
2 (SARS-CoV-2), and Dengue virus (DENV), offering an advanced understanding into the
mechanisms of viral perseverance in its natural human host cells and for therapeutic discovery.
Realizing the diverse dynamics of various viral infections with the capacity to establish an
innovative acuity for therapeutics and mechanics when utilizing humanized mice contributes a
formerly inaccessible insight into human-specific viral pathogenesis and treatment. We recently
developed a new and advanced humanized mouse model by co-transplanting human syngeneic
neural progenitor cells (NPC). The employment of dual humanized mice permits the use of
human-specific pathogens and allows us to study their interaction with re-created parts of the
human immune system or human brain glia. We found that infection of dual humanized blood and
brain mice with ZIKV resulted in high plasma viral loads with extensive dissemination observed
primarily in the brain and spleen. The comprehensive repopulation with human astrocytes and
the amplified infiltration of peripheral immune cells into the brain of dual reconstituted mice
allowed insight into the role of astrocytes during viral infection. This novel mouse model explored
the glial-neural-immune communications during ZIKV infection. Our model presents a strategic
platform for investigating potential therapeutics to prevent or treat emerging viral infections with
involvement of the central nervous system.
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Chapter 1. Introduction
Research on human-specific viruses is infinite as new and re-emerging viruses
continue to pose a serious hazard worldwide. As emerging pathogens reach epidemic or
pandemic status, emphasis is aimed towards mechanistic pathogen modeling and
treatment advancement and validation. Modeling viral pathogenesis has many challenges,
including the ability to recapitulate infection mechanisms and explore innovative
therapeutic strategies for infection eradication in a physiologically pertinent environment.
Numerous models have been established for the evaluation of human viral infections
beginning from in vitro cell lines to in vivo animal models. Though in vivo models, using
mice, hamsters, and non-human primates (NHPs), have allowed investigation into many
significant viral pathogens, they are restricted in demonstrating complete viral mechanics
of human infection.
In vivo studies using mouse models have been essential for both basic and
translational research for many years (McGonigle & Ruggeri, 2014). Albeit mice can
provide indispensable evidence regarding viral properties and treatment, they are limited
by their evolutionary variances and their aptitude to genuinely recapitulate human-specific
diseases in a physiologically relevant setting. These limitations demand an increase in the
use of NHP for infectious disease research. NHPs are vital for the collection of preclinical
data prior to testing in humans. Regrettably, the use of NHPs is unaffordable when utilizing
large sample sizes and special housing facilities to manage and handle the primates.
Therefore, the employment of humanized mice capable of representing human-specific
viral infections permits the use of human-specific pathogens with much larger sample
sizes at a much more reasonable cost than NHPs (Shultz, Ishikawa, & Greiner, 2007).
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Consequently, humanized mice have been established as an indispensable model
for studying human-specific viral pathogenesis. Humanized mice have a comprehensive
human immune system created by transplantation of either human peripheral blood
mononuclear cells (PBMC), hematopoietic stem cells (HSC), or the combination of a
human tissue xenograft with HSC (Brehm, Wiles, Greiner, & Shultz, 2014). These human
immune cells, including lymphoid and myeloid lineages, repopulate their appropriate
physiological location within the mouse lymphatics. Humanized mice permit humanspecific viral pathogenesis due to the natural spread of the viral infection through its
primary tissue reservoirs, eliciting both an innate and adaptive human immune response.
Human cell transplantation into mice allows the investigation of human-specific pathogens
to study of viral infection progression, immune response, and treatment approaches
(Kuruvilla, Troyer, Devi, & Akkina, 2007).

1.1. Emerging Viruses
There is continuous emergence of diverse viruses around the world posing threat for
human life. Studies on pathogenesis of the emerging viruses are critical not only for
pathogen classification but also for therapeutic development. Still there are no promising
vaccines or treatment strategies for many of the viruses resulting in a continuous epidemic
and lack of preparedness against re-emergence. To study the pathogenesis or therapeutic
strategies of these human specific viruses, suitable animal models are critical to contribute
insight into viral infection and treatment.
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1.2. SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus that
causes coronavirus disease 2019 (COVID-19) in humans. Currently, there are nearly 270
million total confirmed cases of SARS-CoV-2 infection in the ongoing pandemic, with the
total number of deaths surpassing five million people worldwide.
SARS-CoV-2 enters cells using angiotensin-converting enzyme 2 (ACE2) as its
primary receptor (Zhou et al., 2020). Since ACE2-mediated angiotensin II (Ang ll)
degradation plays a vital role in the pathogenesis of severe lung failure after infection, the
severity of the disease is directly related to the dynamics and binding capacity of ACE2
(Kai & Kai, 2020). There is evidence that many patients with COVID-19 are asymptomatic
or have only mild symptoms; nonetheless, they can transmit the virus to others. It is
challenging to screen for asymptomatic infections, making it more difficult for national
control and prevention of this epidemic (Gao et al., 2021). A viral test confirms a current
infection. Presently, two types of viral tests can be used: nucleic acid amplification tests
(NAATs) and antigen tests. An antibody serology test could tell you if you had a past
infection but should not be used to diagnose a current disease (www.CDC.gov).

1.3. HIV-1
HIV-1 is a retrovirus that primarily infects human CD4+ T lymphocytes and
macrophages. As the viral replication continues, depletion of CD4+ T cells and the
resulting immune suppression make the host extremely vulnerable to viral-induced tumors
and opportunistic infections. Although antiretroviral therapies efficiently block HIV-1
replication, the challenge is to accomplish this for the entire lifespan.
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Furthermore, chronic inflammation is a symbol of HIV-1 infection that continues
despite treatment. An urgent need remains to grasp better the mechanisms powering HIV1 pathogenesis and classify new targets for therapeutic intervention. The metabolic
pathways of macrophages and CD4+ T cells determine their predisposition to infection,
the perseverance of infected cells, and the formation of latency. Immunometabolism also
shapes immune responses against HIV-1, where cell metabolic products are key drivers
of inflammation during infection (Sáez-Cirión & Sereti, 2021).

1.4. Dengue
Dengue viruses (DENV) is a single-stranded positive-sense ribonucleic acid virus
with 10,700 bases, and belongs to the family Flaviviridae, genus Flavivirus. DENV are
transmitted to people by the bite of an infected Aedes species mosquito. Nearly 50 percent
of the world’s population live-in high-risk areas where Dengue is the leading cause of
illness. Approximately 400 million people get infected with dengue annually of which 100
million get sick, and 50,000 die from severe dengue complications.
Dengvaxia, a vaccine to prevent the DENV, is approved and accessible in many
countries for people aged 9 to 45 years. The World Health Organization warns that the
vaccine should only be given to persons with previously confirmed dengue virus infection
(www.CDC.gov). The inability to control the dengue mosquito vectors overlapped with
dramatic urban growth, globalization, and changing lifestyles are high-risk factors for this
virus to resurface (Murugesan & Manoharan).
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1.5. Zika Virus
Zika Virus (ZIKV) is a mosquito-borne flavivirus that primarily affects brain causing
neurologic dysfunction in humans due to its high neurotropism. ZIKV has a singlestranded positive-sense RNA genome (Agnello, Abel, Elfahal, Knight, & Zhang, 1999). It
is associated with severe congenital disabilities in newborns, including microcephaly,
myelitis, encephalitis, and sensory neuropathy (Vesnaver et al., 2017) (Mlakar et al.,
2016). In adults, ZIKV has been linked to Guillain-Barre syndrome, motor dysfunction, and
even auditory and ocular neurosensory problems (Cofré, 2016; do Rosário et al., 2016).
Most infected individuals have very mild symptoms, including fever, conjunctivitis,
headache, joint pain, and skin rash, with onset usually 2-7 days after the mosquito bite
(Simpson, 1964).
The first human infection with ZIKV was reported in Nigeria in 1954. Still the
identification was subsequently questioned due to the high prevalence of other flaviviruses
in the area, including Dengue, Yellow fever virus, West Nile virus, and Japanese
encephalitis virus(Macnamara, 1954). Thus, slow and silent transmission in the absence
of severe disease and large outbreaks allowed ZIKV to go undetected while spreading
(Baud, Gubler, Schaub, Lanteri, & Musso, 2017). Despite all our breakthroughs since the
beginning of the ZIKV outbreak, many questions remain unanswered, and further
pathogenesis studies are still required.
Incessant spread of viral infections caused by the re-emerging worldwide threat of
ZIKV requires investigation using in vivo models capable of mirroring human disease
development and therapeutic responses (Fauci & Morens, 2016).
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1.6. Current Pharmacological Developments In Treatment, Vaccines,
And Prevention Of ZIKV
Presently there is no approved small-molecule-based drug or vaccine to prevent
or efficiently treat ZIKV infection (Barouch, Thomas, & Michael, 2017). Numerous vaccine
candidates have been tried in animal models to date, producing variable degrees of
immunization to ZIKV infection. Most are either based on nucleic acids, inactivated
viruses, live attenuated viruses, or subunits of ZIKV (Pattnaik, Sahoo, & Pattnaik, 2020).
Several vaccine candidates are currently in phase I clinical trials, with only one (VRC5283)
DNA-based vaccine, in phase II of a clinical trial (Gaudinski et al., 2018). Studies have
shown that CD8+ cells are the foundation of this adaptive immune response against ZIKV
(Badolato-Corrêa et al., 2018). However, CD4 T cells, particularly the Th1 phenotype,
combined with IFNγ, could indirectly permit the establishment of an effective response
against ZIKV (Lucas et al., 2018). A few MAbs targeting viral protein E have revealed
decent results which look for quaternary-dependent epitopes in conserved regions of both
ZIKV and DENV (Barba-Spaeth et al., 2016).
Sofosbuvir, an anti-HCV-approved molecule, has shown promising antiviral effects
against ZIKV in vivo and in vitro, but it has yet to be tested on humans in clinical trials. A
vast variety of drug complexes have been tested with different potential effectiveness seen
in all, yet none have been applied in the treatment of ZIKV, so the search for the perfect
compound is still ongoing (da Silva, Oliveira Silva Martins, & Jardim, 2018). Since
progress has been very slow in the prophylaxis and treatment of ZIKV infection, most of
the approaches used to avoid new epidemics are based on the regulation of the mosquito
vector.
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Organoids have been used for drug screening and have advantages compared to
traditional 2D culture and animal models, as they more accurately mimic the
environmental settings that would be present within the organism, as well as displaying
the communication between different cell populations. They more closely mirror the
architecture of the original organ or tissue, which allows researchers to estimate better
how potential therapeutic agents would enter the organ and act within it (Rossetti, Koch,
& Ladewig, 2019). Besides using brain organoids to study ZIKV pathogenic mechanisms,
they have also been used to test drug formulations against ZIKV infection (Watanabe et
al., 2017). Since there has not been a molecule or vaccine tested so far that has been
entirely effective against ZIKV, nanotechnology could provide another method for the
treatment of ZIKV infection and the elimination of the mosquito vector (Campos et al.,
2020).
However, mechanisms of brain cell pathology and disturbances in the homeostasis
of human brain microenvironment due to ZIKV infection still needs further investigations.

1.7. Brain Microenvironment Under Homeostasis
The central nervous system (CNS) microenvironment is closely observed and
controlled by different cellular types of machinery. Astrocytes function as the hinge in
maintaining CNS homeostasis, managing neurotransmitter release, and forming the
blood-brain barrier (BBB). There is evidence indicating that astrocytes participate in the
local innate immune responses facilitated by a variety of cellular receptors involved in
innate immunity, including Toll-like receptors, double-stranded RNA-dependent protein
kinases, nucleotide-binding oligomerization domains, and mannose receptors and
components of the complement system (Bsibsi, Ravid, Gveric, & van Noort, 2002). After
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activation, astrocytes can secrete soluble mediators, such as CXCL10, CCL2, BAFF, and
interleukin-6, which influence innate and adaptive immune responses (Farina, Aloisi, &
Meinl, 2007).
As the most profuse cell types in the human CNS, astrocytes and
oligodendrocytes, have prominent roles in brain homeostasis and metabolism. The
communications between lymphocytes and monocytes recruited into the nervous system
drive glial activation during progressive viral infection (González-Scarano & MartínGarcía, 2005). If a disease model can correctly reproduce the complicated features of an
infection of the nervous system, in one physiological system, it must have both human
immune and glial elements (Gorantla, Poluektova, & Gendelman, 2012). The importance
of this model is emphasized by the ability to study specific glial transcriptional hallmarks
that closely mirror human illness (Gelman et al., 2012).

1.8. Brain Microenvironment Under Infection
Preserving the CNS microenvironment after infection, injury, inflammatory and
degenerative diseases depend on proper control of glial homeostatic functions. The
disruptions are caused by environmental, microbial, and endogenous factors that
jeopardize ongoing nervous system functions. The ultimate result is neuronal injury,
dropout, and nerve connection loss, which underlie the pathobiology of bacterial, parasitic,
and viral infections. The imbalance is triggered by innate glial-immune pro-inflammatory
and adaptive immune responses, which disturb the brain’s metabolic functions and
communication capabilities (W. Li et al., 2016).
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In the cases of infectious, degenerative, and inflammatory disorders of the CNS,
microglial stimuli directly influence the direction the disease will be driven. Viral infections
can cause parainfectious encephalomyelitis, commonly referred to as acute disseminated
encephalomyelitis (ADEM). The condition is driven by an antigen-antibody attack, where
autoimmunity happens because of widespread neuroinflammation in the brain and spinal
cord with severe demyelination and white matter damage. ADEM is usually triggered after
infection with various viruses that include, but are not limited to ZIKV, influenza, varicellazoster, measles, mumps, rubella, cytomegalo-, entero- and herpes simplex viruses. Next,
the viral invasion of the CNS induces disease due to a productive infection in neurons,
progenitors, accessory glial, or endothelial cells. These invasions are highly dependent on
the pathogen, immune status of the host, and host immune responses and are commonly
associated with substantial morbidity and mortality (McNicholl, Smith, Qari, & Hodge,
1997). Another cause of encephalitis is related to inflammatory responses that arise
because of the viral infection of accessory cells, especially monocytes, macrophages, and
microglia (He et al., 1997). This direct involvement of neuronal destructive activities is
induced by cellular and viral neurotoxic proteins (Sørensen et al., 2008). Undeniably, the
development of dementia usually but not always is linked with the virus (Adle-Biassette et
al., 1999). Compensatory immune responses can limit viruses and diminish disease when
aided by therapeutic treatments. Considering the limited penetrance of drugs across the
blood-brain barrier (BBB) and comorbid conditions like aging, drug abuse, and
coinfections (Devlin et al., 2012), insistent neuroinflammation and viral reservoirs hiding
in the brain continue to prevent the CNS function from restoring (Thompson, Cherry, Bell,
& McLean, 2011). When viewing neuroinflammation as a cause for a wide range of
disorders of variable etiology, a key therapeutic goal is the control of the brain’s
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microenvironment regardless of the disease (Schneeberger, Tierney, & Mandler, 2016).
The reconstruction of the brain’s innate immune function in sustaining its metabolic
purpose and homeostasis is crucial for restorative neuronal vitality (Benarroch, 2005).

1.9. Strategies To Restore Brain Homeostatic Microenvironment After
Infection
Drug penetrance across the BBB and the access of therapeutic agents to damaged
brain areas remains a limitation (Pardridge, 2005). There are still questions on how BBB
disruption occurs and can be reversed and how chemical alteration of drugs can advance
therapeutic delivery (Gabathuler, 2010) (Meairs & Alonso, 2007). Chemical modifications
of drugs to increase lipophilicity

allow more accessible transport through the BBB,

concealing them with lipophilic particles to make pro-drugs, attaching targeting molecules,
and packaging them into nanoparticles or exosomes were explored despite the limitations
with each approach (Dash et al., 2011) (Hall et al., 2016) (Pathan et al., 2009).
Changes in cellular phenotype can affect the brain’s microenvironment by creating
a pro-inflammatory setting that speeds neuronal injury and disease pathogenesis
(Heneka, Kummer, & Latz, 2014). Granting the CNS was always thought to be immuneprivileged, activation and transformation of resident and peripheral immune cells during
the pathogenesis of neurodegenerative diseases confirm that immune system status and
brain hemostasis are tightly cohesive. Research also proposes that there are lymphoid
switches firing in the brain (Wilson, Weninger, & Hunter, 2010). Lymphocyte activation
and successive induction of chemokines like CXCL8, CCL2, and pro-inflammatory
mediators like inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor
necrosis factor–α (TNF-α) cooperatively serve to rush the dispersion of peripheral immune
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cells into the CNS (Kurkowska-Jastrzebska, Wrońska, Kohutnicka, Członkowski, &
Członkowska, 1999; Rivest, 2009). Effector memory T cells migration from the periphery
generates leukocyte-glial crosstalk that intensifies neuroinflammation and limits neuronal
endurance (Mallapragada et al., 2015). Cutting-edge immunopharmacological agents are
being developed as neuroprotective approaches either to block the attraction of the
circulating immune cells to the CNS by reestablishing the BBB or to induce antiinflammatory signals in the CNS (Wilson et al., 2010). The pro-inflammatory
microenvironment that remained uncontrolled or even deteriorated after viral infection
counters the benefits of blocking over-activated excitatory synapses or other therapies
(Williams, Eugenin, Calderon, & Berman, 2012).

1.10. Non-Human Primate Models For ZIKV Infection
Numerous parallel findings from mice studies have also been recapitulated in nonhuman primates (X. F. Li et al., 2016) (Osuna et al., 2016). In rhesus macaques, ZIKV
RNA was confirmed in plasma one day after subcutaneous inoculation with ZIKV. ZIKV
RNA was detected in the brain, cerebrospinal fluid, saliva, and urine, for at least three
weeks (Dudley et al., 2016).
An inactivated virus vaccine-induced ZIKV-specific neutralizing antibodies and
fully protected monkeys against ZIKV strains. The same purified immunoglobulin from the
vaccinated monkeys showed passive protection when adoptive transfer studies were
conducted. A combination of a plasmid DNA vaccine and a single-shot recombinant
rhesus adenovirus serotype 52 vector expressing ZIKV prM-Env also triggered
neutralizing antibodies and completely protected monkeys from ZIKV challenge (Abbink
et al., 2016).
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1.11. Mouse Models For ZIKV
Since immunocompetent wild-type adult mice are highly resistant to ZIKV infection,
a common approach has been to infect neonatal mice to study pathogenesis, as they are
much more vulnerable to infection. Mouse models of ZIKV pathogenesis in adult
immunocompromised mice have shown that the virus can accumulate in the brain, blood,
spleen, spinal cord, kidney, and eye. ZIKV pathogenesis studies using Ifnar1−/− mice have
been critical in recapitulating features of human disease, including placental infection and
trans-placental transmission, limb paralysis and neuroinvasive disease (Miner & Diamond,
2017). It has been shown that 6-week-old mice deficient in three interferon regulatory
transcription factors (IRF3, IRF5, and IRF7) were severely susceptible to infection with
ZIKV and developed CNS infection that resulted in apoptosis of brain cells (H. Li et al.,
2016). Experiments with congenital infection of immunocompromised Ifnar1−/− mice with
ZIKV through intravaginal or subcutaneous route caused similar abnormalities, including
intrauterine growth restriction and fetal demise (Yockey et al., 2016). Intravenous injection
of SJL mice with extremely high doses (e.g., ~1010–1011 PFU) of ZIKV induced
microcephaly and intrauterine growth restriction (Cugola et al., 2016). The epidemiological
data advocates that infection anytime throughout the first and second trimesters in
humans correlates with the most severe fetal disease (Pacheco et al., 2020).
Transgenic mice encompassing the whole viral genome or individually expressed
proteins and the brains of animals injected with viral proteins or human infected cells
reflect only disease components (Gorantla et al., 2012). The deficiency of human glial
cells and variances in responses to the virus, between species, joined with functional
system complexities limit mechanistic insights (Oberheim et al., 2009).
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1.12. Humanized Mouse Models For ZIKV
A major deficiency with the animal models used up to this point has been the failure
to directly evaluate human immune responses during ZIKV infection. Humanized mice
(hu-mice), with a transplanted human immune system, can theoretically overcome these
problems.
Bone marrow, liver and thymus (BLT) mice are made by HSC transplantation
combined with engraftment of matched human fetal liver and thymus under the kidney
capsule of adult immunodeficient mice (Schmitt et al., 2018). Primary and secondary
lymphatic organs develop in BLT mice with human cells present in spleen, thymus, bone
marrow, liver, lymph nodes, gut, and reproductive organs (Shultz, Brehm, GarciaMartinez, & Greiner, 2012). Human immune responses can be produced by human T cells,
B cells, macrophages and dendritic cells, which are crucial components of the human
immune system (Wege, Melkus, Denton, Estes, & Garcia, 2008) (Ito, Takahashi, Katano,
& Ito, 2012). BLT mice allow both human antibody responses and HLA-restricted cellular
immune responses (Melkus et al., 2006) (Seung & Tager, 2013). One disadvantage is the
development of lethal GvHD in some animals with longer period of engraftment.
The human peripheral blood lymphocytes (hu-PBL) model uses adult
immunodeficient mice with the BALB/c-Rag1nullγcnull or BALB/c-Rag2nullγcnull genetic
background, that are then injected intraperitoneally with human peripheral blood
mononuclear cells (PBMC). Though unable to initiate multilineage hematopoiesis, as this
mouse is transplanted with a predetermined number of mature human immune cells, it
supports human T cells, B cells, macrophages, monocytes, dendritic, and natural killer
cells. Hu-PBL mice do not require preconditioning by irradiation prior to engraftment of
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PBMC. Thus, large groups of humanized mice from a multitude of donors can be
generated relatively quickly, which promotes a wide variety of donor variations for testing.
This model is ideal for pursuing new gene therapy strategies as transplanted cells can be
altered before injection into mice. While the effortlessness of hu-PBL preparation and the
ability to use many donors to create the transplanted human immune system is beneficial,
this model is limited by the wide donor cell variation, producing inconsistent engraftment
and graft versus host disease in mice, seen as early as one month after transplantation.
Hu-mice are generated by transplanting CD34+ human hematopoietic stem cells
(HSC) into immunodeficient mouse liver at birth. Hu-mice make great candidates for viral
pathogenesis studies as they can produce human immune responses and were previously
shown to generate virus-specific antibodies to agents such as HIV and DEN (Akkina,
2013). NOD/scid-γcnull (NOD/Shi-scid, NOG, or NOD/LtSz-scid, NSG) mice transplanted
with human CD34+ (HSC) have become instrumental models to study viral infection due
to graft endurance and longevity and the ability to establish a chronic viral infection
(Ishikawa et al., 2005).
Nevertheless, research of innate glial cell communication after ZIKV infection are
stalled due to the lack of relevant small-animal models with human brain cells.

1.13 Dual Humanized Blood And Brain Mouse Model.
To combat the limitation of the lack of virus susceptible human cells in the brain, a
mouse model that is dually humanized with blood and brain was created by injecting
newborn NOD/SCID/IL2Rγc−/− mice both with human NPCs and HSC. This investigational
method resulted in human astrocyte and oligodendrocyte repopulation in anatomically
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symmetrical white matter and periventricular mouse brain regions. RNA sequencing was
used to examine the influence of human cells engraftment on the mouse transcriptional
profile in designated brain regions. Glial humanization of mouse brain with a human
peripheral immune system induced diffident yet widespread transcriptional changes
connected with multiple biological processes, including synaptic transportation,
angiogenesis, ion channel activities, and axonal growth (Li, Gorantla, et al. 2017).

1.14 Hypothesis
Various genetically modified mouse models and NHPs have been utilized for ZIKV
research. To this date, mice represent the most common species used in ZIKV
experiments (Aliota et al., 2016) (Lazear et al., 2016) (Rossi & Vasilakis, 2016). Each
model provided significant insight into the numerous complications associated with ZIKV
infection while also having its own limitations, such as the mice being immune deficient.
Many challenges remain, like timing dynamics of infection and cell-to-cell interactions in
various tissue environments.
Dual humanized mice with human blood and brain cells were selected to study
ZIKV infection in the periphery and viral dissemination to the brain. This NSG mouse strain
lacks mouse immune cells and engraft and support human lymphocytes in the blood,
brain, and various organs.
We hypothesized that the dual humanized mouse will be an appropriate
model to study ZIKV pathogenesis in the periphery and in the brain.
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We also hypothesized that the human cells in both periphery and in brain are
required for ZIKV productive infection and spread, since cell free virus could not
mount infection in the brains of non-humanized mice.
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Chapter 2. Methods
2.1. Humanized Mice Generation
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice obtained from Jackson Laboratories,
Bar Harbor, ME and raised under detailed pathogen-free settings at the University of
Nebraska Medical Center (UNMC) in accordance with the ethical guidelines stated by the
National Institutes of Health for maintenance of laboratory animals were used for
generating humanized mice. Newborn pups were irradiated at 1 Gy with an RS‐2000 × ‐
Ray Irradiator (Rad Source Technologies, Buford, GA). After irradiation, cluster of
differentiation 34 (CD34)+ HSCs obtained from human cord blood using magnetic beads
(CD34 + selection kit; Miltenyi Biotec Inc., Auburn, CA, USA) were transplanted by an
intrahepatic (i.h.) injection of 50,000 cells/mouse in 20 μl phosphate-buffered saline (PBS)
using a 30-gauge needle(Ishikawa et al., 2005).Engraftment of human immune cells are
evaluated by flow cytometry.

2.2. Dual Reconstituted Brain And Blood Mouse Generation
Human neural progenitor cells (NPCs) were isolated from human fetal brains and
human hematopoietic stem cells (HSCs) were isolated from human liver, kindly provided
by the University of Washington Medical Center Laboratory of Developmental Biology
(R24HD000836-51). Informed consent was attained from all tissue donors and all clinical
investigation was directed according to the values stated in the Declaration of Helsinki.
The UNMC Scientific Research Oversight Committee (SROC) and Institutional Review
Boards at the University of Washington Medical Center and UNMC approved this protocol.
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Cells were isolated from human fetal brains as previously explained (Nunes et al., 2003).
In brief, single-cell suspensions were cultured in NS-A medium (STEMCELL, Mountain
View, Canada), containing N2 supplement (1:100; Fisher Scientific, Waltham, MA, USA),
LIF (10 ng/ml; Sigma-Aldrich, St. Louis, MO, USA), neural survival factor-1 (NSF1; 1:50;
Lonza, Walkersville, MD, USA), basic fibroblast growth factor (bFGF; 20 ng/ml;
STEMCELL), epidermal growth factor (EGF; 20 ng/ml; Fisher, MA, USA), for 14 days
before passage. Four hours before injection, neurospheres were dissociated into singlecell suspension with 0.25% Trypsin (Gibco, Grand Island, NY, USA).
Fetal liver tissues were dissociated into single-cell suspensions using special C
tubes (Miltenyi Biotec, USA) on the Miltenyi Biotec Dissociator machine in combination
with enzymes including DNase I (10mg/ml; Sigma-Aldrich, St. Louis, MO, USA),
Hyaluronidase IV (10mg/ml; Sigma-Aldrich, St. Louis, MO, USA), and Collagenase II
(10mg/ml; Gibco, Grand Island, NY, USA). Magnetic MicroBeads (Miltenyi Biotec, USA)
specific for CD34+ HSCs and LS columns (Miltenyi Biotec, USA) were used to isolate
stem cells for humanizing mice.
Irradiated newborn NSG mice were either transplanted intracranially with NPCs
(105 cells/mouse) and intrahepatically with (105 cells/mouse) CD34+ HSCs from the same
donor to generate the blood and brain mouse or exclusively with either NPCs or CD34+
HSCs to generate brain only or blood only mice, respectively (Li,Gorantla, et al. 2017).
Immune cell engraftment was evaluated by flowcytometry.
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2.3. Flow Cytometry
Mouse blood samples were collected from the facial vein or by direct heart
puncture immediately following euthanasia in ethylene diamine tetraacetic acid (EDTA)
vials and stored at 4 °C. (BD Microtainer, Franklin Lakes, NJ, USA). Blood cells were
centrifuged at 1800 rpm for 8 min. Blood cells were resuspended in a fluorescenceactivated cell sorting (FACS) buffer (2% FBS in phosphate-buffered saline) and incubated
with a combination of fluorescently conjugated antibodies against human immune cells,
CD45+ fluorescein isothiocyanate (FITC), CD3+ Alexa Fluor 700 (AF700), CD4+
allophycocyanin (APC), CD8+ Brilliant Violet 421 (BV421) and CD14+ Phycoerythrin (PE),
CD19+ Phycoerythrin-Cyanin 5 (PE-Cy5), for 30 min at 4 °C. All isotype controls and
antibodies were bought from BD Biosciences, USA. Red blood cells were lysed with FACS
lysis solution diluted to 1X with distilled water. (BD Biosciences, USA). Then the stained
cells were washed with FACS buffer and fixed with 2% paraformaldehyde before acquiring
the samples. Data acquisition was carried out with Attune acquisition software (Thermo
Fisher, USA) in an Attune Flow cytometer. Data were analyzed using FLOWJO analysis
software v10.2 (Tree Star, USA). Gates were set according to the proper control
population.

2.4. Zika Virus Infection Experimental Scheme
Irradiated humanized mice are inoculated with ZIKV at 22 weeks of age and blood
is collected every 7 days for plasma viral load and flow cytometric analyses of human cells
until the endpoint at day 28. Tissues are harvested and processed for immunohistology,
RNAscope, and ZIKV RNA quantification. Both experimental animals and non-humanized
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controls were infected with 150 µl of the Puerto Rico ZIKV (PRVABC59) at 104 PFU per
animal injected intraperitoneally.

2.5. Immunohistochemistry
Mouse brains and spleens were fixed with 4% paraformaldehyde (PFA) for
24 hours at room temperature and then embedded in paraffin wax. Antigen unmasking of
paraffin-embedded 5-μm thick tissue sections was performed with Declere/Trilogy
Solution (Sigma-Aldrich, St Louis, MO, USA) following the manufacturer’s guidelines.
Immunohistochemical staining was performed using an EXPOSE Mouse and Rabbit
Specific horseradish peroxidase (HRP)/ Diaminobenzidine (DAB) Detection Kit for IHC
(Abcam, Cambridge, MA, USA) as per manufacturer’s instructions. To detect human
immune cells in spleens CD3 Ms mAb Clone F7.2.38 (1:25 dilution Dako, USA) and CD20
Ms mAb Clone L26 (1:50 dilution Dako, USA) were used. To detect human cells in mouse
brains, HLA-DQ/DR/DP (CR3/43) (1:100 dilution; Novus Biologicals, Littleton, CO, USA),
human-specific GFAP Ms mAb (1:100 dilution; Genetex, GTX27806), and human-specific
OLIG2 Ms mAb (1:100 dilution; Genetex, GTX60398) was used. To detect mouse
astrocytes, Rb pAb GFAP (1:1000 dilution; Dako) and mouse microglia, Rb pAb for Iba1
(1: 500 dilution; Wako) was used. To detect ZIKV in the brain, we used a rabbit polyclonal
antibody against Zika virus NS2B protein diluted 1:100 (Genetex, GTX133308). The nuclei
were counterstained with Harris hematoxylin. Non-humanized mouse tissues were used
in every staining protocol as a negative control to test the antibodies’ specificity to human
proteins.
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2.6. Histological Stains
Mouse brains and spleens sections were stained with a Hematoxylin and Eosin Kit
(Abcam, Cambridge, MA) according to the manufacturer’s protocol. Deparaffinization was
performed using xylenes, and the washes were performed using 100% ethanol and
distilled water.
Staining of the myelin sheath in mouse brain sections was performed using a Luxol
Fast Blue Kit (ScyTek Logan, UT) according to the manufacturer’s guidelines. In brief,
slides were incubated with LFB reagent overnight in a 60°C oven followed by steps
outlined in the protocol.

2.5. RNAscope
RNAScope® (Advanced Cell Diagnostics, Hayward, CA) was performed to detect
human GFAP, and ZIKV on paraffin-embedded sections as described by the
manufacturer’s instructions. Briefly, 5 μm thick dehydrated and deparaffinized formalinfixed paraffin-embedded brain and spleen sections were incubated with H2O2 at room
temperature for 10 min, followed by target retrieval solution for 8 min at 100 °C, and then
treated with protease IV at 40 °C for 15 min in a HybEZ hybridization oven. The
hybridization with the target probe, pre-amplification, amplification, and chromogenic
detection using DAB was performed as per manufacturer’s guidelines in a HybEZ oven at
40 °C. For human GFAP, 8ZZ probe named Hs-GFAP-No-XMm in C2 targeting 1298-1781
base pairs of NM_001131019.2 (cat no 300031-C2) and for ZIKV, a 20ZZ probe named
V-Zika-pp in C1 targeting 1550-2456 of base pairs of KJ776791.1 (cat no 463781-C1) was
used. To show colocalization of human astrocytes, mouse astrocytes, and mouse
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microglia with ZIKV RNA we combined IHC with RNAscope according to manufacturer’s
guidelines.

2.6. Immunofluorescence
Paraffin wax embedded five-micron sections were blocked with 10% normal goat
serum. Primary antibodies used in the study were anti-human HLA- DQ/DR/DP(CR3/43)
(1:100; Novus Biologicals, Littleton, CO, USA), human-specific GFAP Ms mAb (1:100;
Genetex, GTX27806) and rabbit polyclonal antibody against Zika virus NS2B protein
(1:100; Genetex, GTX133308). Secondary antibodies were Alexa Fluor 594-conjugated
goat anti-Rb IgG (1:200; Invitrogen, Grand Island, NY, USA) and Alexa Fluor 488conjugated goat anti-ms IgG (1:200; Invitrogen). Nuance EX multispectral imaging system
(Cambridge Research Instruments) was used for immunofluorescent imaging at a 20X
and 40X magnification.

2.7. ELISA
ZIKV-specific IgM antibody responses were measured in serum samples using a
commercially available anti-ZIKV IgM (Abcam, Cambridge, MA) enzyme-linked
immunosorbent assay (ELISA) kit. In brief, 1:100 serum dilutions were performed in
duplicate and added to pre-coated plates provided in the kit. The ELISA was executed
according to the manufacturer’s directions, and the plate was read at 450 nm.

2.8. ddPCR On Plasma, Spleen, And Brain RNA To Detect ZIKV
The ddPCR assay was performed based on the water-oil emulsion droplet
technology, using the ddPCR™ Supermix for Probes reagents in the QX200™ Droplet
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Digital™ PCR system (Bio-Rad Laboratories, Hercules, CA). A QIAamp Viral RNA mini kit
(Qiagen, Germany) was used to isolate Zika viral RNA from 40ul of mouse plasma
samples as per the manufacturer’s instructions. Trizol reagent and the accompanying
protocol were used to isolate RNA from 50mg of brain and spleen tissues. To isolate
individual splenocyte populations, magnetic microbeads (Miltenyi Biotec, USA) against
human CD4, CD8, and CD19 were used to purify these lymphocyte populations from
single cell processed spleen samples and then passed through LS columns (Miltenyi
Biotec, USA) to remove impurities.
The ddPCR was performed as described above. The forward primer 5’TTGGTCATGATACTGCTGATTGC-3’
CCTTCCACAAAGTCCCTATTGC-3’

and
along

CGGCATACAGCATCAGGTGCATAGGAG-3’

reverse
with

FAM

primer
probe

5’5’-

were used to detect Zika virus in plasma,

spleen and brain samples.

2.9. Statistical Analysis
Data were analyzed and plotted using GraphPad Prism 7 (Graph pad, USA).
The p-value< 0.05 was considered to indicate a statistically significant difference. A nonparametric Mann-Whitney test was used to calculate significance in the dual reconstituted
group versus brain only group and ZIKV infected group versus uninfected group. A nonparametric Kruskal-Wallis test with a Two-Way ANOVA was used to calculate significance,
comparing brain and spleen RNA per microgram of tissue between the three mouse
groups.
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Chapter 3. Results
3.1. Wide Distribution Of NPC-Derived Glial Cells In Mouse Brain
Human lymphoid and brain progenitor cells are transplantation into mice one day
after birth, which generates the human blood and brain dual reconstituted (huBB) mouse
(Figure 1A). NPCs were injected into the lateral ventricle, followed by intrahepatic injection
of HSCs.
Irradiated newborn NSG mice were injected intracranially with human NPCs and
intrahepatically with CD34+ HSC from the same donor. NPCs were attained from fetal
human brains to yield neurospheres, from which a single cell suspension was obtained
and transplanted at 105 cells per mouse. Assortments of neuronal cells arising from
parental progenitors encompassing glial fibrillary acidic protein (GFAP)/microtubuleassociated protein (MAP) glial progenitors, glutamic acid decarboxylase 67 (GAD67) and
class III β-tubulin (Tuj-1) +, and nestin/GFAP neural progenitors with radial glia
characteristics were present. These data indicated that the NPCs derived from fetal brains
retained multilineage competence.

3.2. Human Immune Cell Reconstitution In The Mouse
Humanization using CD34+ HSCs produces human T cells, B cells, monocytes,
and dendritic cells in bone marrow and secondary lymphoid structures.
Human cell reconstitution in the blood of 4-month-old mouse was evaluated by flow
cytometry (Figure 2A). A six fluorochrome-based immune cell flow panel was used to
assess percentages of human cells in mouse blood. First, the R1 gate is analyzed to
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determine total CD45 cells followed by ratio of CD3 to CD19 human lymphocytes from the
same CD45 gate. From total CD3, a quadrant gate was created to see the ratios of CD4
to CD8 T cells. Finally, CD14 population is drawn from the main CD45 plot. The R2 gate
in the initial side-scatter (SSC) vs. forward scatter (FSC) dot plot is used to ensure all
myeloid cells are incorporated. The distribution and enumeration of human cells in mouse
peripheral blood before inoculation with ZIKV is critical when grouping mice for an
experiment. Mice lacking cells in either of the six categories are removed from the study
to ensure that only well-reconstituted mice are selected. Each dot (N=12) represents an
individual mouse (Figure 2B).
In summary, we were able to successfully engraft neonatal NSG mice with NPCs.
This model allowed us to investigate how glial-immunocyte crosstalk is affected by ZIKV
infection.

3.3. ZIKV Infection Induced Lethality In Humanized Mice
Humanized mice are infected with ZIKV at 22 weeks of age, and blood is collected
every seven days for plasma viral load and flow cytometric analyses of human cells until
the endpoint at day 28. Tissues are harvested and processed for immunohistology,
RNAscope, and ZIKV RNA quantification. Scheme of experiment is presented on Figure
3.
Body temperature and weights were measured daily after inoculation with ZIKV
until the endpoint at Day 28 in ten mice. Body temperature, in degrees Celsius, was
measured in mice after inoculation with 150µl of ZIKV (PRVABC59) i.p. at 104 PFU (Figure
4A). The bodyweight of infected mice was measured in grams (Figure 4B). All weights
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(mean- 20g) and body temperatures (mean- 32°C) remained reasonably constant
throughout the experiment, with fluctuations seen in just a few mice.
During the 28-day duration of the experiment, ZIKV infected dual reconstituted
mice showed increased lethality when compared to non-humanized mice. Non-humanized
mice maintained one hundred percent survival throughout the experiment, whereas
humanized mice succumbed to death around 28 days post-infection (Figure 4C).

3.4. ZIKV Infect Human Immune Cells
Plasma was collected every three days from dual humanized and non-humanized
mice. The viral load levels were maintained throughout the study in the dual reconstituted
mice (Day1 mean- 900 copies/ml and Day 28 mean- 950copies/ml) compared to nonhumanized mice, whose levels diminished (Day1 mean- 40 copies/ml and Day28 mean0 copies/ml) below the level of detection (10 copies/ml) over time (Figure 5).
To

evaluate

ZIKV

infection

in

the

spleens

of

humanized

mice,

immunohistochemistry was performed on 5µm thick paraffin-embedded sections.
Combinations of CD20 and NS2B protein and CD3 and NS2B protein and RNAscope
targeting ZIKV RNA were used to visualize infection in mouse spleens (Figure 6A). We
observed colocalization in both CD3 and CD20 in combination with NS2B protein. Zika
NS2B staining is in red and human immune cell staining is in brown.
When we used RNAscope to identify ZIKV RNA in mouse 5um thick paraffinembedded spleen sections we saw many clusters of brown dots with cell like morphology
dispersed throughout the tissue. We also saw many individual brown dots which represent
individual copies of ZIKV RNA.
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To quantify the infection level in different human immune cells, we isolated
individual human cell populations from mouse spleens using magnetic beads specific for
human CD4, CD8, and CD19 (Figure 6B). ddPCR was used to quantify ZIKV copies per
100ug of total spleen RNA (N=6). The CD4 population expressed an average of 23 copies,
CD8 expressed nearly 40 copies, and CD19 showed the highest expression of ZIKV with
55 copies per 100ug of total spleen RNA.
Additionally, total RNA was extracted from spleens using the Trizol method and
ddPCR was performed on the samples to quantify ZIKV RNA (Figure 6C). Viral load
analysis from spleens of non-humanized and humanized mice demonstrated that nonhumanized mice could not support productive infection in the spleen like the humanized
mice. Humanized mice displayed as much as 108 copies per microgram of viral RNA in
their spleens.

3.5. ZIKV Induce Humoral Immune Response In Humanized Mice
The humoral immune response was measured in infected mouse serum diluted
(1:100) by using an IgM ELISA kit (Figure 7). A total of 19 serum samples were assayed
in duplicate. The absorbance was read at 450 nm for IgM detection in serum. For IgM
detection, the assay cutoff for control is >7 and the equivocal cutoff is 9-11. Values higher
than eleven are considered unquestionably positive, N=8. Spectrophotometric analysis
showed that eight out of nineteen samples showed unquestionably positive readings
confirming the presence of a humoral immune response to the ZIKV infection in dual
reconstituted mice. Ten of the mice showed equivocal readings.
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3.6. ZIKV Infect Mouse Neurons In The Presence Of Human Immune
And Glial Cells.
We analyzed the presence of ZIKV in mouse brain and compared non-humanized
and humanized animals. RNA was extracted from brains using the Trizol method to
analyze brain infection. ddPCR was performed on samples from the dual reconstituted
group and non-humanized group to quantify ZIKV RNA (Figure 8A). We observed
significantly more infection at around 106 copies of ZIKV RNA in the dual humanized
mouse brains. Combined RNAscope with immunohistological analysis of brain tissues
showed the presence of ZIKV RNA (brown) at varying levels in different parts of the brain
including hippocampus, cortex, caudate putamen, thalamus and hypothalamus (Figure
8B). Detailed examination revealed that the viral RNA was mainly localized in mouse
neurons. We also observed colocalization of ZIKV RNA with all three cell targets including
human astrocytes, mouse astrocytes, and mouse microglia (Figure 8C).

3.7. Human Glial Cells Facilitate The Spread Of ZIKV Infection On
Mouse Neurons
To determine the role of brain cells in disseminating Zika infection, three different
groups of mice were utilized - Hu-blood, Hu-brain, and Hu-blood/brain (Figure 9A). Mice
in the Hu-blood group did not receive i.c. injections of NPC, only i.h. injections of HSC at
birth. Mice in the Hu-brain group did not receive i.h. injections, only i.c. injections of NPC
at birth. While the Hu-blood/brain group received both NPC and HSC injections at birth.
The hu-blood and hu-brain groups served as periphery only and brain only controls
respectively, compared to the dual reconstituted hu-blood/brain group.
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Plasma viral load (VL) was monitored for the duration of the experiment in the three groups
of mice (Figure 9B). ZIKV was undetectable after 10 days in the brain only group, similar
to non-humanized mice, suggesting the importance of peripheral human cells in the initial
establishment of infection. The VL levels remain consistent throughout the 28-day
observation period in the blood only (mean- 100 copies) and in dual reconstituted blood
and brain (mean- 150 copies) groups. This data was consistent with histological analysis
and advocates that presence of human immune cells is required for productive ZIKV
infection.
We used a non-parametric Kruskal-Wallis test to quantitate and compare ZIKV
RNA per µg of spleen tissue between the three groups of mice in the study (Figure 9C).
Data confirmed that the dual reconstituted group (107 copies) has significantly (p<0.01)
higher levels of ZIKV RNA in the spleen compared to blood (105 copies) and brain only
(102 copies) group, reiterating the importance of both human immune and glial system for
the infection in these mice.
Viral infection in brains of the three mouse groups (Figure 9D) was analyzed using
ddPCR. Comparison of ZIKV RNA per ug of brain tissue between the three groups of mice
demonstrated that the dually reconstituted blood and brain group (106 copies) has
significantly, (p<0.01) higher levels of ZIKV RNA in the brain when compared to the two
other groups, with blood having 102 copies; and brain 103 copies). Data suggested that
both human immune cells and the human brain cells are required to generate brain
infection.
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3.8. ZIKV Infection Deplete Human Astrocytes
To determine the effects of ZIKV infection in the astrocytes, dual RNAscope was
performed. Comparison of hGFAP RNA (red) and ZIKA RNA (blue) between brain only
group and blood and brain group showed increased copies of viral RNA in the dual
reconstituted group. We also noticed that there is a reduction in the level of GFAP RNA
in dual reconstituted mice (Figure 10). RNAscope revealed that dual humanization caused
peripheral human immune cells, carrying ZIKV, to infiltrate the brain and disseminate the
virus which eliminates the human astrocytes at a significantly higher rate than when there
is no peripheral support.
To confirm our findings, immunohistochemical staining using an anti-hGFAP
primary antibody to detect astrocytes was performed in the brain sections of dual
reconstituted group and the brain-only group (Figure 11A). Nuance spectral quantification
revealed that there is a significantly higher number of human astrocytes in the brain-only
group (MFI 0.008) when compared to the dual reconstituted group (MFI 0.004). This data
suggests that there are significantly (p< 0.0001) more astrocytes being killed by ZIKV in
the dual reconstituted group due to robust immune cell infiltration from the periphery
carrying lethal ZIKV into the brain.
In parallel, we also quantified total astrocytes in the ZIKV infected and uninfected
mice (Figure 11B) using chromogen based and fluorescence-based detection. Nuance
spectral quantification of chromogen-based detection method revealed that there is a
significantly (p< 0.0001). higher number of human astrocytes in the uninfected mice (MFI
0.007) compared to infected (MFI 0.004) demonstrating that ZIKV is responsible for killing
human astrocytes after inoculation.
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Nuance spectral quantification of fluorescently stained astrocytes reinforced a
significantly higher number of human astrocytes in the uninfected mice proving that ZIKV
is accountable for killing human astrocytes after inoculation. (Figure 11C).

3.9. ZIKV Infection Induce Significant Neuropathology
Histopathological examination of the brain tissues was performed to understand
the effects of ZIKV infection in the neurons and microglia. Hematoxylin and Eosin stained,
5um thick paraffin-embedded brain sections in dual reconstituted mice displayed various
signs of damage caused by infiltrating virus (Figure 12). Histopathological examinations
showed microglial hyperplasia in the cortex of the dual reconstituted mice. There was
increased acidosis and retraction of pyramidal neurons in the hippocampus and apoptosis
was observed in the Purkinje neurons. Analysis of blood and brain only group did not show
any pathological signs.
Examination of brain tissues using Luxol Fast Blue staining between different
groups of mice revealed that severe demyelination in the corpus callosum and cerebellum
regions in the dual reconstituted group compared to other groups. We also validated demyelination is significantly higher in the dual humanized group than non-humanized mice
(Figure 13).
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Figure 1 The scheme of dual humanized mice generation
A, Scheme displaying human lymphoid and brain progenitor cell transplantation into mice
one day after birth, which generates the human blood and brain (huBB) mouse. Neural
progenitor cells (NPC) were injected into the lateral ventricle followed by intrahepatic (ih)
injection of hematopoietic stem cells (HSC).
B, Humanization using CD34+ HSC produces human T cells, B cells, monocytes, and
dendritic cells in bone marrow and secondary lymphoid structures. Humanization with
NPC allows for human astrocytes, oligodendrocytes, neurons, and other human neural
cells to develop inside the mouse brain by 20 weeks of age.
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Figure 2. Flow Cytometric analysis of human cell reconstitution in mouse blood at
4 months of age, prior to inoculation with ZIKV.
A, Flow Cytometric analysis of human cell reconstitution in mouse blood at 4 months of
age, prior to inoculation with ZIKV. Basic gating strategy to obtain accurate cell counts
and percentages of human cells in mouse blood. First, the R1 gate is expanded to evaluate
total CD45 cells. Followed by ratio of CD3 to CD19 human lymphocytes from CD45 gate.
From total CD3 a quadrant gate is created to see the ratios of CD4 to CD8 T cells. Finally,
CD14 population is drawn from the main CD45 plot. The R2 gate in the initial SSC vs.
FSC is used to ensure all myeloid cells are incorporated. B, Distribution of human cells in
mouse peripheral blood before inoculation with ZIKV. Each dot represents an individual
mouse. N=12
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Figure 3. Scheme depicting the timeline of observation and checkpoints after
transplantation of human blood and brain progenitor cells at birth.
Humanized mice are inoculated with ZIKV at 22 weeks of age and blood is collected every
7 days for plasma viral load and flow cytometric analyses of human cells until the endpoint
at day 28. Tissues are harvested and processed for immunohistology, RNAscope, and
ZIKV RNA quantification.
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Figure 4. Body temperature and weights after ZIKV infection.
A, Body temperature and weights were measured daily after inoculation with ZIKV until
endpoint at Day 28. Body temperature (degrees Celsius) in mice infected with 150ul i.p.
4

using ZIKV (PRVABC59) at 10 PFU. B, Body weight in grams (N=10). C, Survival of
Humanized and Non-Humanized mice over a 28-day period. N=26
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Figure 5. ZIKV peripheral viral load in humanized and non-humanized mice
To further investigate peripheral VL in blood, RNA was extracted from serum using a Viral
RNA Kit and ddPCR was used to quantify total VL at specific timepoints throughout the
study.
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Figure 6. Human immune cells infection by ZIKV.
A, ZIKV infection in humanized mouse spleen. Combinations of CD20 and NS2B protein
and CD3 and NS2B protein and RNAScope targeting ZIKV RNA. B, Magnetic beads
specific for human CD4, CD8, and CD19 were used to isolate individual human cell
populations from mouse spleens. ddPCR was used to quantify ZIKV copies/100ug of total
RNA. N=6. C, to further investigate spleen infection RNA was extracted from spleens using
the Trizol method.
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Positive >11 (n=8)

Equivocal 9 to 11 (n=9)

Negative < 7 (n=1)

Figure 7. Serum ZIKV IgM.
Serum ZIKV IgM at the specified days post infection in mice inoculated I.P. with PR ZIKV
isolate. The green line represents the assay cutoff control (0-7) for IgM detection. The blue
line represents the equivocal cutoff (9-11). Values higher than eleven are considered
unquestionably positive. The absorbance was read at 450 nm for IgM detection in serum.
N=18.
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Figure 8. Detection of ZIKV in non-humanized and dual humanized mouse brains
A, To further investigate brain infection RNA was extracted from brains using the Trizol.
ddPCR was perfomed on samples from the three different groups of mice to quantify ZIKV
RNA. B, Scanned images of hGFAP (red) and ZIKV RNA (brown) in various regions of the
brain. C, Immunohistological staining targeting different cell types combined with ZIKV
RNA scope identified colocalization of Zika RNA with human astrocytes positive for human
GFAP, mouse astrocytes positive for mouse GFAP and mouse microglia identified using
iba-1 antibody.
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Figure 9. Experimental scheme to test hypothesis and ZIKV spread.
A, To investigate the hypothesis we made three different mouse groups. The first one has
only human immune system-which is called blood only. Here the mice were reconstituted
only with hematopoietic stem cells intrahepatically. Second group was reconstituted only
with human neural progenitor cells injected into the brain ventricles. These are called brain
only mice and will only develop neural progenitor cell derived human brain cells. The third
group were the dual reconstituted mice with both human immune system and human brain
cells. B, Plasma VL monitored for the duration of the experiment. C, A non-parametric
Kruskal-Wallis test was used to generate the graph representing a comparison of ZIKV
RNA per ug of spleen tissue between the three groups of mice in the study. D, A nonparametric Kruskal-Wallis test was used to explore the viral infection in brains of the three
mouse groups.
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Figure 10. Depletion of human astrocytes by ZIKV infection
Comparison of hGFAP and ZIKA RNA double staining between Brain only group and
Blood and Brain group. Dual humanization causes peripheral human immune cells,
carrying ZIKV, to infiltrate the brain and disseminate the virus which eliminates the human
astrocytes at a significantly higher rate than when there is no peripheral support.
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Figure 11. Quantitation of the human astrocytes in the brains of different mouse
models without and with ZIKV infection.
A and B, Human astrocytes were quantified from brightfield images using our Nuance
camera system. When using a non-parametric Mann-Whitney test we see significantly
more human astrocytes in the Brain Only group and in the Uninfected group when
compared to our Dual reconstituted group and to ZIKV infected group because there are
more human astrocytes being killed with the presence of ZIKV. C, Fluorescent Nuance
microscopy displaying ZIKV infected vs. uninfected stained sections targeting human
astrocytes.
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Figure 12. Morphological changes in the humanized and non-humanized mouse
brains induced by ZIKV infection.
Hematoxylin and Eosin (H&E) stained 5 µm brain sections in dual reconstituted mice
displaying various signs of damage caused by infiltrating immune cells from the periphery.
Green arrows represent microglial hyperplasia, blue arrows represent acidosis and
retraction of pyramidal neurons, and black arrows represent apoptotic Purkinje neurons.
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Figure 13. ZIKV induced demyelination in dual humanized mouse brains.
Luxol Fast Blue staining comparison of different brain regions between the three different
groups of mice used in the study. Non-humanized mice provided additional validation that
de-myelination is significantly higher in the dual hu-BB group than any other group.
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Chapter 4. Discussion
With the recurrence of ZIKV infection worldwide, a serious need for an in vivo
model capable of mimicking infection mechanics and immune responses has become
critical. Numerous in vivo models have been studied for ZIKV infection. Still, they need
genetic modifications, as observed in the A129/AG129 mouse models, or restricted
sample size and outrageous prices associated with the use of NHP models. To resolve
the need for a physiologically appropriate model encompassing a complete peripheral
human immune system and human glial cells that enable high samples sizes at a much
more reasonable cost, we have developed the dual reconstituted humanized mouse
model.
We designed an inimitable mouse model comprised of both human immune
system and human astroglial cells in the brain, allowing us to explore the glial-immune
communications during ZIKV infection and identify cells with affinity to ZIKV in the CNS.
Studies revealed that NPC could differentiate into numerous neural lineages,
including astrocytes, oligodendrocytes, and neurons. Research confirmed that
transplantation of human neurosphere-derived NPC is possible in a living mouse with
viable human-derived neurons and glial cells (Uchida et al., 2000). However, early
transplantation is vital to enhance migration responses of human glia in mouse brains
(Windrem et al., 2014) (Han et al., 2013).
Human NPC transplanted into immunodeficient NSG mice at an early postnatal
age verified a wide-ranging astroglial distribution pattern. Many human astrocytes
repopulated multiple regions along whiter matter tracts after five months. Amazingly, the

55
hu-NPC-derived cells replaced their murine counterparts in regions such as hippocampus,
CC, and cerebellum. A substantial number of human cells positive for Olig2, a determining
factor for oligodendrocyte differentiation, were present. Glial-biased differentiation seen in
these dual humanized brains can be defined in two ways. Firstly, the in-situ fate of NPC
is restricted by the local white-matter environment (Roy et al., 1999). The molecular
indicators in the recipient white matter may offer the migration path for human cells and
initiate a glia-oriented fate, perhaps without exogenous support. Secondly, an essential
feature of brain development is that neurons can be created before astroglia. Development
of these neural progenitor cells in the presence of leukemia inhibitory factor (LIF) and
fibroblast growth factor (FGF) may push these cells toward a point where glial
predisposition is increased with affiliated loss of neurogenic potential (Elkabetz et al.,
2008).
The comprehensive repopulation with human astrocytes and the amplified
infiltration of peripheral immune cells into the brain of dual reconstituted mice allowed
insight into the role of astrocytes during viral infection. Human astroglia engraftment
encouraged wide-ranging changes in the mouse transcriptional profile. Mouse genes
associated with biological processes including synaptic transportation, axon growth,
angiogenesis, ion transport, and memory and learning were found to be slightly up
regulated. Even though it is difficult to foresee the significance of human astroglia
engraftment on mouse brain neurological function and milieu at this point, previous studies
confirmed human astrocytes have higher structural complexity and functional ability
compared to mouse brain cells (Oberheim et al., 2008) and engraftment of human
astroglia differentially improve both long-term potentiation and learning in mice (Han et al.,
2013).
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We found that the presence of human astrocytes facilitates the spread of ZIKV on
mouse neurons. Histological analysis of ZIKV infected mouse tissues from both dual
humanized and partially humanized mice has provided evidence regarding cellular targets
and dissemination patterns comparable to the pathology observed in human patients. The
results revealed viral antigen in the areas of the hippocampus, corpus collosum, and
cerebral cortex, with prominent cell targets appearing to be neurons, astrocytes, and
microglial cells. Degenerative changes were observed in the CA layer of the hippocampus.
Degeneration and damage in this particular area led to noticeably diminished neuronal
capacity. This type of neuropathogenesis is a classical characteristic of ZIKV infection in
both adult and fetal infections (Ritter, Martines, & Zaki, 2017). The most common
abnormality linked with ZIKV infection is microcephaly observed in human fetuses and
newborns exposed to the pathogen (Wen et al., 2021) (Limonta et al., 2018) (Devhare,
Meyer, Steele, Ray, & Ray, 2017).
As efforts are focused on understanding ZIKV infection, persistence, and
transmission, the characterization of animal models to better reflect viral pathogenesis
remains an important priority. While multiple animal models demonstrated to be effective
in sustaining viral infection and modeling pathogenesis, they come with many limitations.
Currently published mouse models require genetic manipulation of the mouse innate
immune system in order to become susceptible to ZIKV infection.
Data from a study where intravenous viral inoculation was compared to infection
from a mosquito bite demonstrate that significantly higher levels of IFN-γ are produced in
humanized mice when infected by mosquitoes, advocating that syringe delivery of virus
does not stimulate the same immune responses as infection by a mosquito bite (Mota &
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Rico-Hesse, 2011). Furthermore, mosquito saliva, not only the bite, played an important
role in innate immune system activation and the subsequent elevated levels of interferon
signaling, causing a more severe disease in humanized mice than when they were
infected with a needle. We did not analyze the presence of human IFNγ in dual humanized
animals, but we assume that ZIKV induce human cytokine production, including IFNγ that
could contribute to the brain pathology and observed demyelination (Cox, Mota,
Sukupolvi-Petty, Diamond, & Rico-Hesse, 2012).
We also found the presence of virus in human immune cells that reflect findings
similarly as in humans (Messias et al., 2019). Only when human immune cells were
present, were we able to find ZIKV infected human cells in the brain. This is a mechanism
of how the virus could enter the central nervous system.
To address the need of a suitable animal model that comes with a much more
reasonable cost, we have investigated the use of dual reconstituted humanized mice for
modeling ZIKV infection. Dual reconstituted humanized mice demonstrate viral infection
with the potential for immune responses as well as histopathology detected in tissues
critical for viral persistence. Our studies advocate that dual reconstituted humanized mice
serve to be an essential animal model for ZIKV pathogenesis. Overall, dual reconstituted
humanized mice, with both a human peripheral and glial communication present a suitable
platform for investigating ZIKV pathogenesis and potential therapeutics for treatment.
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